GET DAILY SIGNALSCoreCivic (CXW) Posts +28.2% Revenue Growth in Q3 2026, Beats Estimates
Key Takeaways
- CoreCivic reported third-quarter 2026 revenue of $744.1 million, up 28.2% year over year and above the roughly $705.8 million consensus estimate.
- Adjusted earnings per share (EPS) of $0.49 beat analyst expectations of $0.43 by about 14%.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $117.8 million, topping the $109.3 million estimate.
- Normalized funds from operations (FFO), a measure of operating cash generation, rose to $0.75 per diluted share from $0.48 in the prior-year quarter.
- Management raised its full-year 2026 adjusted EPS guidance to a midpoint of $1.77, helped by stronger demand and a reduced share count.
- For additional context, explore CoreCivic's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Discover actionable, AI-driven trade ideas by exploring Trending AI Robots.
Why These Results Matter
CoreCivic's results matter because the company sits at the intersection of federal immigration enforcement policy and private corrections infrastructure. Its revenue mix has shifted sharply toward U.S. Immigration and Customs Enforcement (ICE), which has driven rapid occupancy gains and reactivation of previously idle facilities. The third quarter also captured the completion of four major facility sales to the U.S. government, a move that reshaped the balance sheet and meaningfully reduced the share count. For investors, this report offers a read on detention demand trends, per-diem pricing, facility economics, and how management is deploying a large influx of cash. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
CoreCivic posted third-quarter 2026 revenue of $744.1 million, an increase of 28.2% from the year-ago period, exceeding the consensus estimate near $705.8 million. Adjusted EPS came in at $0.49, above the $0.43 analysts had projected. Adjusted EBITDA reached $117.8 million, ahead of the $109.3 million consensus figure.
Normalized FFO, which strips out special items, was $69.9 million, or $0.75 per diluted share, compared with $52.1 million, or $0.48 per diluted share, a year earlier. The quarter also reflected the completion of four facility sales to the U.S. government, with gross proceeds of about $2.2 billion and net proceeds of roughly $1.6 billion. Management raised full-year 2026 adjusted EPS guidance to a midpoint of $1.77 and set adjusted EBITDA guidance near a $444 million midpoint.
Market Reaction and Investor Sentiment
CoreCivic entered the quarter with investor attention focused on ICE detention volumes, which had dipped in early 2026 before rebounding. The company's ability to beat revenue and adjusted EPS expectations, while raising full-year guidance, signals that demand and pricing held up better than the market anticipated. The completed facility sales and the associated accelerated share repurchase (ASR) also reframed the investment story around capital returns and a leaner share base, factors that tend to support per-share metrics even as management flags that sold facilities will now operate under modified management contracts.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most important variable remains ICE detention demand and occupancy levels across CoreCivic's reactivated facilities. The company has indicated it expects to begin receiving detainees at the newly awarded Appleton Facility in the fourth quarter of 2026, with full activation targeted for the second quarter of 2027. Investors will watch whether occupancy at recently activated sites such as California City and Diamondback continues to climb. From what I see, I’m watching this closely because any sustained improvement here could support further per-share growth.
A second area to monitor is the transition of the four sold facilities to government ownership. CoreCivic expects to continue managing these sites, but the terms of those contracts may change, and the contracts carry termination provisions tied to government funding. These dynamics could weigh on future revenue and margin comparisons.
Finally, capital deployment remains a key theme. The company launched a $500 million accelerated share repurchase and still holds a sizable authorized repurchase capacity. How management balances buybacks, the integration of the recently acquired Clinical Solutions Pharmacy business, and potential additional government facility acquisitions will shape the outlook for adjusted EPS and FFO over the coming quarters.
How Tickeron’s AI Tools Support My Research
I often turn to Tickeron’s AI Screener when evaluating stocks like this one. It helps me quickly filter for technical patterns, fundamentals, and industry trends, which adds useful context to the earnings data. The tool has become a regular part of how I screen for comparable names and spot potential breakout candidates without spending hours on manual analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CXW in downward trend: price dove below 50-day moving average on October 14, 2026
CXW moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 38 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 74%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for CXW crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CXW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for CXW entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 35 of 53 cases where CXW's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on CXW as a result. In 67 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for CXW just turned positive on October 29, 2026. Looking at past instances where CXW's MACD turned positive, the stock continued to rise in 39 of 53 cases over the following month. The odds of a continued upward trend are 74%.
Following a +3.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where CXW advanced for three days, in 234 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
CXW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CXW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.098) is normal, around the industry mean (3.026). P/E Ratio (24.031) is within average values for comparable stocks, (1.906). CXW's Projected Growth (PEG Ratio) (55.830) is very high in comparison to the industry average of (5.749). Dividend Yield (0.058) settles around the average of (0.316) among similar stocks. P/S Ratio (1.442) is also within normal values, averaging (2.085).
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a prison real estate investment trust
Industry MiscellaneousCommercialServices
Advertisement